Emcure Pharma and Mold-Tek Packaging report strong Q2FY27 growth
Emcure Pharmaceuticals saw a 34 per cent profit rise while Mold-Tek Packaging recorded a 36 per cent jump in net profit.
Emcure Pharmaceuticals and Mold-Tek Packaging Limited have both reported significant increases in net profit for the second quarter of the 2027 financial year (Q2FY27).
According to Business Standard, Emcure Pharmaceuticals reported a 33.7 per cent year-on-year growth in consolidated net profit to ₹325.5 crore. The company's revenue from operations grew 24.2 per cent to ₹2,820.4 crore, driven by international business and steady domestic growth.
Emcure's domestic revenue reached ₹1,155.3 crore, up 12 per cent year-on-year, led by women's health, cardio-metabolics, and central nervous system segments. The international business, which made up 59 per cent of consolidated revenue, reported sales of ₹1,665.2 crore, a 34.5 per cent increase.
Emcure Pharmaceuticals Chairman, Managing Director and Chief Executive Officer Satish Mehta said the company expects business momentum to sustain into H2FY27. The company also filed the Lenacapavir injection dossier with the World Health Organization (WHO) and the US Food and Drug Administration (USFDA).
Separately, ThePrint reported that Mold-Tek Packaging Limited saw its net profit increase by 36.06 per cent to ₹21.09 crore for Q2FY27. The company's sales volume grew 10.08 per cent to 11,028.46 MT, supported by an improved product mix.
Mold-Tek's pharma packaging business registered 26.30 per cent year-on-year volume growth, while food and FMCG packaging grew 23.70 per cent. Chairman and Managing Director J Lakshmana Rao said the company delivered pharmaceutical performance despite turbulent times and geopolitical disruptions.